tiprankstipranks
Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart
Company Announcements

Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart

Don't Miss our Black Friday Offers:

Eledon Pharmaceuticals ( (ELDN) ) has provided an update.

Eledon Pharmaceuticals has announced promising initial results from a trial involving their investigational antibody, tegoprubart, in type 1 diabetes patients following islet transplantation. The first two participants achieved insulin independence, with enhanced islet engraftment and glucose control, compared to traditional tacrolimus-based treatments. These findings, presented at a major summit, highlight tegoprubart’s potential as a safer, effective alternative in managing transplant rejection and advancing diabetes treatment.

Learn more about ELDN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEledon Pharmaceuticals price target lowered to $20.50 from $28 at Ladenburg
TipRanks Auto-Generated NewsdeskEledon Pharmaceuticals Reports Strong Q3 2024 Results
TheFlyEledon Pharmaceuticals reports Q3 EPS (32c), consensus (31c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App